WO2023104904A3 - The sars-cov-2 and variants use two independent cell receptors to replicate - Google Patents
The sars-cov-2 and variants use two independent cell receptors to replicate Download PDFInfo
- Publication number
- WO2023104904A3 WO2023104904A3 PCT/EP2022/084833 EP2022084833W WO2023104904A3 WO 2023104904 A3 WO2023104904 A3 WO 2023104904A3 EP 2022084833 W EP2022084833 W EP 2022084833W WO 2023104904 A3 WO2023104904 A3 WO 2023104904A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cov
- sars
- ace2
- lsr
- replication
- Prior art date
Links
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 abstract 8
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 abstract 8
- 108010077695 lipolysis-stimulated receptor Proteins 0.000 abstract 7
- 241001678559 COVID-19 virus Species 0.000 abstract 6
- 235000021588 free fatty acids Nutrition 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 230000029812 viral genome replication Effects 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 241000494545 Cordyline virus 2 Species 0.000 abstract 1
- 108020000999 Viral RNA Proteins 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 210000000805 cytoplasm Anatomy 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000002121 endocytic effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000007502 viral entry Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure relates to a compositions and methods for prevention and/or treatment of COVID-19 disease caused by the SARS-CoV-2. The Angiotensin-Converting Enzyme 2 (ACE2) that delivers viral RNA into the cytoplasm was heretofore the sole known SARS- CoV-2 receptor. Disclosed herein is the identification of another SARS-CoV-2 receptor. Namely, the Lipolysis Stimulated Receptor (LSR). LSR provides an endocytic route as effective for the replication of SARS-CoV-2 as ACE2. LSR and ACE2 contributions to viral replication are coordinated by free fatty acids (FFA). Unsaturated FFA irreversibly suppress SARS-CoV-2 capacity to bind ACE2. At the same time, both saturated and unsaturated FFA activate LSR. Activated LSR endocytoses ACE2 competent and incompetent SARS-CoV-2 yielding immediate or delayed production of ACE2 competent progeny. Disclosed herein are compositions and methods directed toward both ACE2 and LSR mediated routes of viral entry and replication, which reduce the severity and transmission of SARS-CoV-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2113141 | 2021-12-08 | ||
FRFR2113141 | 2021-12-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023104904A2 WO2023104904A2 (en) | 2023-06-15 |
WO2023104904A3 true WO2023104904A3 (en) | 2023-07-20 |
Family
ID=85132800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/084833 WO2023104904A2 (en) | 2021-12-08 | 2022-12-07 | The sars-cov-2 and variants use two independent cell receptors to replicate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023104904A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111088283A (en) * | 2020-03-20 | 2020-05-01 | 苏州奥特铭医药科技有限公司 | mVSV viral vector, viral vector vaccine thereof and mVSV-mediated novel coronary pneumonia vaccine |
WO2021045836A1 (en) * | 2020-04-02 | 2021-03-11 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
ATE244763T1 (en) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | ACHIEVEMENT OF HOMOZYGOTE THROUGH TARGETED GENETIC EVENTS |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
DE60144063D1 (en) | 2000-12-18 | 2011-03-31 | Dyax Corp | DIRECTED LIBRARIES GENETICALLY PACKAGED |
EP1887088A1 (en) | 2006-07-20 | 2008-02-13 | Transmedi SA | Transcription infidelity, detection and uses thereof |
EP3753947A1 (en) | 2007-09-14 | 2020-12-23 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
JP6881813B2 (en) | 2014-04-23 | 2021-06-02 | モデルナティーエックス, インコーポレイテッド | Nucleic acid vaccine |
US20200085852A1 (en) | 2015-08-05 | 2020-03-19 | Curevac Ag | Epidermal mrna vaccine |
EP4349404A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
EP4148427A1 (en) | 2016-03-18 | 2023-03-15 | Genclis | Molecular origin of allergy |
-
2022
- 2022-12-07 WO PCT/EP2022/084833 patent/WO2023104904A2/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111088283A (en) * | 2020-03-20 | 2020-05-01 | 苏州奥特铭医药科技有限公司 | mVSV viral vector, viral vector vaccine thereof and mVSV-mediated novel coronary pneumonia vaccine |
WO2021045836A1 (en) * | 2020-04-02 | 2021-03-11 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
Non-Patent Citations (10)
Title |
---|
BARBERIS ELETTRA ET AL: "Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 22, 16 November 2020 (2020-11-16), pages 1 - 25, XP055854390, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696386/pdf/ijms-21-08623.pdf> DOI: 10.3390/ijms21228623 * |
CARRIQUE LOIC ET AL: "The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer", BIORXIV, 13 August 2020 (2020-08-13), XP093037159, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.08.13.249177v1.full.pdf> [retrieved on 20230404], DOI: 10.1101/2020.08.13.249177 * |
CREECH BUDDY ET AL: "SARS-CoV-2 Vaccines | Vaccination | JAMA | JAMA Network", JAMA, 26 February 2021 (2021-02-26), XP093039331, Retrieved from the Internet <URL:https://jamanetwork.com/journals/jama/fullarticle/2777059> [retrieved on 20230414], DOI: 10.1001/jama.2021.3199 * |
GOC ANNA ET AL: "Abstract", SCIENTIFIC REPORTS, vol. 11, no. 1, 4 March 2021 (2021-03-04), XP055844623, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-021-84850-1.pdf> DOI: 10.1038/s41598-021-84850-1 * |
IDRIS ADI ET AL: "A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19", MOLECULAR THERAPY, vol. 29, no. 7, 1 July 2021 (2021-07-01), US, pages 2219 - 2226, XP055869239, ISSN: 1525-0016, Retrieved from the Internet <URL:https://ars.els-cdn.com/content/image/1-s2.0-S1525001621002562-mmc4.pdf> DOI: 10.1016/j.ymthe.2021.05.004 * |
LADNER JASON T. ET AL: "Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses", CELL REPORTS MEDICINE, vol. 2, no. 1, 1 January 2021 (2021-01-01), pages 100189, XP055847640, ISSN: 2666-3791, Retrieved from the Internet <URL:https://www.cell.com/cell-reports-medicine/pdfExtended/S2666-3791(20)30244-5> DOI: 10.1016/j.xcrm.2020.100189 * |
THEKEN KATHERINE N. ET AL: "The roles of lipids in SARS-CoV-2 viral replication and the host immune response", JOURNAL OF LIPID RESEARCH, vol. 62, 1 January 2021 (2021-01-01), US, pages 100129, XP093037161, ISSN: 0022-2275, DOI: 10.1016/j.jlr.2021.100129 * |
TOELZER CHRISTINE ET AL: "Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein", SCIENCE (AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE), 6 November 2020 (2020-11-06), United States, pages 725 - 730, XP055845592, Retrieved from the Internet <URL:https://www.science.org/doi/10.1126/science.abd3255> [retrieved on 20210928], DOI: 10.1126/science.abd3255 * |
WANG DONGLIANG ET AL: "Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design", VACCINES, vol. 8, no. 3, 3 July 2020 (2020-07-03), XP055865893, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563688/pdf/vaccines-08-00355.pdf> DOI: 10.3390/vaccines8030355 * |
ZHANG MIN ET AL: "LSR Promotes Cell Proliferation and Invasion in Lung Cancer", COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, vol. 2021, 8 March 2021 (2021-03-08), pages 1 - 8, XP093021769, ISSN: 1748-670X, Retrieved from the Internet <URL:https://downloads.hindawi.com/journals/cmmm/2021/6651907.pdf> DOI: 10.1155/2021/6651907 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023104904A2 (en) | 2023-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202193242A1 (en) | CARTRIDGE FOR AEROSOL GENERATING DEVICE | |
MX2020010227A (en) | Constructs targeting cd22 and uses thereof. | |
AR083957A1 (en) | TREATMENT TO MODULATE NK CELLS AND METHODS TO TREAT HEMATOLOGICAL MALIGNITY | |
MA32729B1 (en) | 1-amino acid derivatives | |
MY157525A (en) | Inhibitors of the renal outer medullary potassium channel | |
MX2011012181A (en) | Composition and method for controlling plant diseases. | |
MX2022002198A (en) | Compositions and methods for modulating splicing and protein expression. | |
WO2004050620A3 (en) | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | |
MX2021014465A (en) | Rnai constructs for inhibiting scap expression and methods of use thereof. | |
WO2019175799A3 (en) | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds | |
MX2021013341A (en) | Solid forms of a glyt1 inhibitor. | |
WO2022036126A3 (en) | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION | |
WO2023104904A3 (en) | The sars-cov-2 and variants use two independent cell receptors to replicate | |
MY150817A (en) | Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid | |
ZA202206266B (en) | Pd-l1 antagonist compound | |
GB201312965D0 (en) | Stem cell factor inhibitor | |
MX2022006735A (en) | Substituted nucleoside analogs as prmt5 inhibitors. | |
CL2020002644A1 (en) | Composition to modulate genes responsible for the general functions of the skin, comprising the combination of an extract of hymenaea courbaril and a mixture of sodium and sarcosine cocoylamino acids and potassium aspartate and magnesium aspartate (divisional application 03354-2018) | |
AR110750A1 (en) | METHOD FOR IMPROVING PLANT HEALTH AND ROOT DEVELOPMENT | |
CR8376A (en) | METHOD FOR PRODUCING DERIVATIVES OF (3-OXO-2,3-DIHIDRO-1 H-ISOINDOL-1-IL) -ACETILGUANIDINE | |
CR20230261A (en) | Cocrystal of a cdk inhibitor | |
EA202193054A1 (en) | STABLE COMPOSITIONS OF ALBUVIRTIDE | |
WO2012003477A3 (en) | Inhibition of inflammation bysimultaneous blockade of multiple prostanoid receptors | |
MA33512B1 (en) | INHIBITORS OF CATHEPSIN C | |
MX2022012419A (en) | Adhesive composition for a glue stick. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22850641 Country of ref document: EP Kind code of ref document: A2 |